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Regimens containing three nucleoside reverse-transcriptase inhibitors offer an alter-
native to regimens containing nonnucleoside reverse-transcriptase inhibitors or pro-
tease inhibitors for the initial treatment of human immunodeficiency virus type 1




This randomized, double-blind study involved three antiretroviral regimens for the ini-
tial treatment of subjects infected with HIV-1: zidovudine–lamivudine–abacavir, zidovu-








(71,434) copies per milliliter and a mean CD4 cell count of 238 per cubic millimeter
were enrolled. A scheduled review by the data and safety monitoring board with the use
of prespecified stopping boundaries led to a recommendation to stop the triple-nucle-
oside group and to present the results in the triple-nucleoside group in comparison
with pooled data from the efavirenz groups. After a median follow-up of 32 weeks, 82
of 382 subjects in the triple-nucleoside group (21 percent) and 85 of 765 of those in the
combined efavirenz groups (11 percent) had virologic failure; the time to virologic fail-
ure was significantly shorter in the triple-nucleoside group (P<0.001). This difference
was observed regardless of the pretreatment HIV-1 RNA stratum (at least 100,000 cop-
ies per milliliter or below this level; P≤0.001 for both comparisons). Changes in the
CD4 cell count and the incidence of grade 3 or grade 4 adverse events did not differ sig-




In this trial of the initial treatment of HIV-1 infection, the triple-nucleoside combina-
tion of abacavir, zidovudine, and lamivudine was virologically inferior to a regimen con-
taining efavirenz and two or three nucleosides.
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triple-nucleoside versus efavirenz-containing regimens for hiv-1 infection
 
1851
ntiretroviral therapy for human
 
immunodeficiency virus type 1 (HIV-1) in-
fection decreases viremia, increases CD4





 Current treatment guidelines recommend
initial therapy with one or more protease inhibitors
or a nonnucleoside reverse-transcriptase inhibitor





 Though effective, protease-inhibi-
tor–based regimens are complex and have been as-






nonnucleoside reverse-transcriptase inhibitors are









Triple-nucleoside regimens are an alternative to
regimens containing nonnucleoside reverse-tran-










 with efficacy similar to that of




Triple-nucleoside regimens are among the simplest




We performed a direct comparison of three sim-
ple, protease-inhibitor–sparing regimens for the
initial treatment of HIV-1 infection: a triple-nucle-
oside regimen, a nonnucleoside reverse-transcrip-
tase inhibitor combined with two nucleosides, and
a nonnucleoside reverse-transcriptase inhibitor




Eligible patients were HIV-1–infected adults who
had received no previous antiretroviral therapy and
who had a plasma HIV-1 RNA level of at least 400
copies per milliliter (HIV-1 Monitor Assay, version
1.0, Roche Molecular Systems). Patients were ex-
cluded if they had received immunomodulator or
investigational therapy or vaccines within the pre-
vious 30 days, if they weighed less than 40 kg, or if




We conducted a randomized, double-blind, place-
bo-controlled comparison of three antiretroviral
regimens for the initial treatment of HIV-1 infec-
tion. Subjects were stratified at randomization ac-
cording to their HIV-1 RNA level at screening (at
least 100,000 copies per milliliter or fewer than
100,000 copies per milliliter). The planned dura-
tion of the study was 96 weeks from the enrollment
of the last subject. The study was approved by the
institutional review board of each participating site,
and all subjects gave written informed consent.
Screening evaluations included a review of the HIV
treatment history and documentation of HIV-1 se-
rologic analysis and the plasma HIV-1 RNA level
within 90 days before study entry. The baseline
evaluations included a medical history, a clinical as-
sessment, laboratory tests, measurement of plas-
ma HIV-1 RNA, and a CD4 cell count. In addition, a
plasma sample was obtained at base line and stored
for later HIV-1 genotyping.
Eligible subjects were assigned with equal prob-
ability to one of three study regimens (including
placebos for blinding as necessary) given orally at
standard doses and intervals: zidovudine–lamivu-
dine–abacavir (Trizivir, GlaxoSmithKline), zidovu-
dine–lamivudine (Combivir, GlaxoSmithKline) plus
efavirenz (Sustiva, Bristol-Myers Squibb), or zido-
vudine–lamivudine–abacavir plus efavirenz. Sub-
jects took a total of seven pills per day (including
placebos), divided into two doses. In the event of
toxic effects of the study drugs that were considered
by the site investigator to be treatment-limiting,
the identity of the implicated drug was allowed to
be revealed and substitution of another drug in the
same class was permitted. Stavudine (Zerit, Bris-
tol-Myers Squibb) could be substituted for zidovu-
dine, didanosine (Videx EC, Bristol-Myers Squibb)
could be substituted for abacavir, and nevirapine
(Viramune, Boehringer Ingelheim) could be sub-
stituted for efavirenz.
Subjects were evaluated at weeks 2 and 4, then
every four weeks until week 24, and every eight
weeks thereafter. Each visit included clinical and
laboratory assessments and the measurement of
plasma HIV-1 RNA. In addition, CD4 cell counts
were performed at weeks 4 and 8 and every 8 weeks
thereafter, a lipid panel was obtained every 16
weeks, and a pregnancy test was performed when-
ever pregnancy was suspected. A questionnaire
about adherence to the study regimen was admin-
istered at weeks 4, 12, and 24 and every 24 weeks
thereafter. For subjects who permanently discon-
tinued the study treatment, laboratory tests, HIV-1
RNA measurements, and CD4 cell counts were
performed every eight weeks.
Virologic failure was defined by two successive
HIV-1 RNA values of 200 or more copies per milli-
liter at least 16 weeks after randomization; the date
of virologic failure was recorded as the date when
a
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the first such value was obtained. Suspected viro-
logic failure was to be confirmed within four weeks.
After confirmed virologic failure, the treatment-
group assignment could be revealed. Genotypic re-
sistance testing (TruGene, version 6.0, Visible Ge-
netics) was performed on both the specimen used
to confirm failure (if the HIV-1 RNA level was at
least 500 copies per milliliter) and the stored base-
line specimen, and the results of both tests were re-
ported. If the HIV-1 RNA level was between 200
and 9999 copies per milliliter, the subject could
continue to receive the assigned regimen or switch
to a second study-provided regimen. Subjects with
either a confirmed HIV-1 RNA level of at least 10,000
copies per milliliter or continued treatment-limit-
ing toxic effects despite the substitution of one or
more of the alternative drugs proceeded to a second
regimen. Adverse events were assessed by the site
investigators and were graded according to the tox-





The objectives of the study were to compare the
three regimens in terms of safety, tolerability, and
virologic efficacy. The study was designed to have
86 percent power to show a noninferior rate of vi-
rologic failure with the triple-nucleoside regimen
as compared with zidovudine–lamivudine and efa-
virenz if the failure rates for the two regimens were
the same (defined by a hazard ratio for virologic
failure with an upper 95 percent confidence limit of
less than 1.35) and to have 80 percent power to de-
tect a ratio hazard for virologic failure of 0.70 for
the other pairwise comparisons. With adjustment
for interim analyses and loss to follow-up, it was
determined that a sample of 375 subjects per group
would be needed.
Base-line HIV-1 RNA levels were calculated as
the geometric mean of two measurements obtained
before therapy began. Analyses of time to virologic
failure were performed according to the Kaplan–
Meier method and with the use of log-rank tests
and Cox proportional-hazards models stratified ac-




Changes in the CD4 cell count over time were com-





 Adherence to the study regimen was cal-
culated as the ratio of the number of doses taken to
the number prescribed over a four-day period, and
comparisons of adherence were made with the use





ation between adherence and virologic failure was
assessed by means of a Cox proportional-hazards
model stratified according to the treatment group. 
Analyses of all efficacy variables were performed
on an intention-to-treat basis and included all fol-
low-up data, including data obtained after the dis-
continuation of treatment or virologic failure, from
all randomized subjects to whom study drugs were
dispensed. Data were censored at the time of with-
drawal from the study, and missing evaluations were
ignored. For analyses of adverse events, follow-up
data were censored either 56 days after the perma-
nent discontinuation of treatment or at the time of
withdrawal from the study, whichever came first.
All reported P values are two-sided; P values and
confidence intervals are unadjusted for interim
analyses.
The study was reviewed annually for safety and
efficacy by the data and safety monitoring board of
the National Institute of Allergy and Infectious Dis-





 was used to compare each three-drug





 was used to protect the type I
error rate for sequential monitoring. For the nonin-
feriority comparison of the triple-nucleoside group
with the two groups receiving nucleosides plus efa-





used so that at each interim analysis, consideration
was given to modifying the trial design because of
sufficient evidence to declare noninferiority if the
upper 99.9 percent confidence limit for the hazard
ratio for virologic failure was less than 1.35.
Because of the possibility that the triple-nucleo-
side regimen could be inferior to the two nucleo-
sides plus efavirenz, stopping guidelines were spec-
ified that evaluated the accumulated evidence in the





the lower 95 percent confidence limit of the hazard
ratio for virologic failure was greater than 1.14, it
was recommended that the study design be changed
on the grounds that noninferiority could not be
demonstrated. This stopping rule involves the use




 dividing the type II error
rate (beta=0.14) equally among three planned in-
terim analyses. Given the assumptions behind the
sample-size calculation and the assumption of equal
numbers of person-years of follow-up in all the
study groups, the 1.14 boundary is the limit of the
point estimate for the hazard ratio that would lead
to the rejection of the null hypothesis at the final
analysis (i.e., an upper 95 percent confidence limit
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of less than 1.35). If the accumulated data at any in-
terim review were to be inconsistent with such a re-
sult, it is unlikely that we would ever be able to re-
ject the null hypothesis.
At the second annual review in February 2003,
with the use of data through November 2002, pair-
wise comparisons among the three study groups
showed differences between the triple-nucleoside
regimen and each of the efavirenz-containing regi-
mens that met prespecified stopping guidelines (a
lower 95 percent confidence limit of more than
1.14 for the noninferiority comparison and a bound-
ary P value of 0.003 for the comparison between the
triple-nucleoside regimen and the four-drug regi-
men). The data and safety monitoring board rec-
ommended stopping the triple-nucleoside portion
 
* Plus–minus values are means ±SD. To convert values for weight to kilograms, multiply by 0.45.
† Race or ethnic group was self-reported by the subjects.
‡ The baseline HIV-1 RNA level was calculated as the geometric mean of two measurements obtained before therapy be-
gan and within 30 days before study entry.
§ The baseline CD4 cell count was calculated as the mean of two measurements obtained before therapy began and within 
 
30 days before study entry. Data were missing for one subject. 
 















<20 Yr — no. (%)
20–29 Yr — no. (%)
30–39 Yr — no. (%)
40–49 Yr — no. (%)
50–59 Yr — no. (%)
60–69 Yr — no. (%)














































Weight — lb 138±53 139±56












<500 copies/ml — no. (%)
500–4999 copies/ml — no. (%)
5000–49,999 copies/ml — no. (%)
50,000–99,999 copies/ml — no. (%)
100,000–249,999 copies/ml — no. (%)
250,000–499,999 copies/ml — no. (%)
500,000–749,999 copies/ml — no. (%)
























0–50 — no. (%)
51–200 — no. (%)
201–500 — no. (%)
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of the study, continuing double-blind follow-up of
the other two groups, and analyzing and present-
ing the results with the data for the triple-nucleo-
side group compared with the pooled data from the





A total of 1147 subjects enrolled in the study be-
tween March 2001 and November 2002; 1 subject
inadvertently enrolled twice but was counted only
once. A total of 81 percent of the study subjects were
men, and 60 percent were nonwhite; 11 percent had
used intravenous drugs (Table 1). The mean base-





per milliliter; 43 percent of the subjects had an
HIV-1 RNA level of 100,000 or more copies per
milliliter. The mean baseline CD4 cell count was
238 per cubic millimeter. The treatment groups
were balanced in terms of baseline characteristics.
 
disposition of the subjects
 
After a median follow-up of 32 weeks (range, 0 to
80), 1064 subjects (93 percent) remained in the
study and follow-up was discontinued in 83 sub-
jects (7 percent) for various reasons: the withdraw-
al of consent (in 21 cases), loss to follow-up (in 21
cases), inability to attend visits (in 19 cases), non-
adherence to the study regimen (in 11 cases), se-
vere debilitation (in 4 cases), and death — from
HIV-1–related illness (in 2 cases), metastatic carci-
noma (in 1 case), probable zidovudine-related hep-
atitis (in 1 case), accident (in 1 case), and unknown
causes (in 2 cases). There were no significant dif-
ferences in the rates of discontinuation between the
treatment groups. In all, 1136 subjects (99 percent)
received the study treatment to which they were as-
signed, and 11 subjects (1 percent) never started
the study treatment. A total of 940 subjects (82 per-
cent) continued to receive their initial study regi-
men (with or without substitutions because of
treatment-limiting toxic effects), 32 (3 percent) pro-
ceeded to a second study regimen, and 81 (7 percent)
permanently discontinued study treatment but con-
tinued to be followed.
 
hiv-1 rna level and cd4 cell count
 
Protocol-defined virologic failure occurred in 167
subjects: 82 of the 382 in the triple-nucleoside group
(21 percent) and 85 of the 765 in the combined efa-
virenz groups (11 percent). The time to virologic
failure was significantly shorter in the triple-nucle-
oside group than in the combined efavirenz groups
(P<0.001) (Fig. 1A). Significant differences were
also observed in analyses of the subgroup with a
pretreatment HIV-1 RNA level below 100,000 copies
per milliliter (P=0.001) (Fig. 1B) and the subgroup
with a pretreatment level of 100,000 copies per
milliliter or higher (P<0.001) (Fig. 1C) and in post
hoc analyses of the subgroup with a pretreatment
CD4 count of 100 cells per cubic millimeter or high-
er (P=0.001) and the subgroup with a count below
that level (P<0.001), as well as in the subgroup with
a pretreatment CD4 count of 200 cells per cubic
millimeter or higher (P=0.004) and in the sub-
group with a count below that level (P<0.001).
Figure 2 shows the proportions of subjects with
an HIV-1 RNA level of less than 200 copies per mil-
liliter and with a level below 50 copies per milliliter.
At week 48, 74 percent of the subjects in the triple-
nucleoside group (95 percent confidence interval,
65 to 83 percent) had an HIV-1 RNA level below
200 copies per milliliter, and 61 percent (95 per-
cent confidence interval, 50 to 72 percent) had an
HIV-1 RNA level below 50 copies per milliliter; at
the same time point, the corresponding percent-
ages in the combined efavirenz groups were 89 per-
cent (95 percent confidence interval, 85 to 93 per-
cent) and 83 percent (95 percent confidence interval,
78 to 88 percent). A post hoc analysis designed to
examine the durability of viral suppression in the
subgroup of 923 subjects with at least one HIV-1
RNA value below 200 copies per milliliter during
therapy demonstrated that the time to virologic fail-
ure was shorter in the triple-nucleoside group than
in the combined efavirenz groups (P<0.001) (Fig.
3A). In an analysis including the 780 subjects with
at least one HIV-1 RNA value below 50 copies per
milliliter, a similar difference was suggested, but it
was not statistically significant (P=0.08) (Fig. 3B).
There were no significant differences between
the groups with respect to the change in the CD4
cell count from base line (P=0.58). At week 48, the
results
 
Figure 1 (facing page). Time to Virologic Failure in the 
Study Population as a Whole (Panel A), among Subjects 
with an HIV-1 RNA Level below 100,000 Copies per Milli-
liter before Treatment (Panel B), and among Subjects 
with an HIV-1 RNA Level of 100,000 Copies per Milliliter 
or Higher before Treatment (Panel C).
 
P values and z scores were calculated with the log-rank test.
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mean change in the triple-nucleoside group was an
increase of 174 cells per cubic millimeter (95 per-
cent confidence interval, 151 to 197) and the mean
change in the combined efavirenz groups was an
increase of 173 cells per cubic millimeter (95 per-




Genotypic resistance testing was performed on the
viral samples from 82 subjects in the triple-nucleo-
side group who had confirmed virologic failure (Ta-
ble 2). At baseline, 78 of these subjects (95 percent)
had wild-type virus, the virus from 3 subjects (4 per-
cent) showed substitutions associated with resis-
tance to reverse-transcriptase inhibitors, and no
sample was available for 1 subject. At the time of
confirmed virologic failure, 18 subjects (22 per-
cent) had wild-type virus, 28 (34 percent) had only
the M184V substitution in the reverse transcriptase
(which confers resistance to lamivudine), 9 (11 per-
cent) had the M184V substitution as well as other
substitutions associated with reverse-transcrip-
tase–inhibitor resistance, and 2 (2 percent) had sub-
stitutions associated with reverse-transcriptase–
inhibitor resistance but did not have the M184V
substitution. Sequencing was not attempted in 22
subjects (27 percent) who had HIV-1 RNA levels be-
low 500 copies per milliliter, and virus from 3 sub-
jects (4 percent) could not be sequenced. We do not
report resistance information for the combined efa-





Of subjects reaching the time points, at least 94
percent reported adherence information. The me-
dian rate of self-reported adherence to the study
regimen was 100 percent at weeks 4 (817 subjects),
12 (718 subjects), and 24 (561 subjects), without
significant differences according to the treatment
group (P=0.33, P=0.74, and P=0.69, respectively).
In all the treatment groups, subjects with adherence
of less than 95 percent at week 12 (124 subjects, or
17 percent) had a higher rate of virologic failure
than those with adherence of 95 percent or higher
(594 subjects, or 83 percent) (P<0.001). In a post
hoc analysis, the 195 subjects in the triple-nucleo-
side group who reported 100 percent adherence at
 
Figure 2. Proportions of Subjects with HIV-1 RNA Levels below 200 Copies per Milliliter (Solid Lines) and below 50 Copies 
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week 12 had a higher rate of virologic failure than
the 382 subjects in the combined efavirenz groups




Because of treatment-limiting toxic effects, 94 of
the 1136 subjects who received zidovudine (8 per-
cent) substituted stavudine for zidovudine, 40 of the
759 who received abacavir (5 percent) substituted
didanosine for abacavir, and 46 of the 759 who re-
ceived efavirenz (6 percent) substituted nevirapine
for efavirenz. Suspected hypersensitivity reactions
to study drugs occurred in 27 of the subjects in the
triple-nucleoside group (7 percent) and 59 of the
subjects in the combined efavirenz groups (8 per-
cent). During treatment with the initial regimen,
signs or symptoms of grade 3 toxic effects were ob-
served in 37 of the subjects in the triple-nucleoside
group (10 percent) and 95 of those in the combined
efavirenz groups (13 percent); signs or symptoms
of grade 4 effects were observed in 9 subjects (2 per-
cent) and 17 subjects (2 percent), respectively. Also
during treatment with the initial regimen, laborato-
ry evidence of a grade 3 toxic effect was found in 70
of the subjects in the triple-nucleoside group (19
percent) and 132 of those in the combined efavi-
 
Figure 3. Post Hoc Analysis of Time to Virologic Failure in the Subgroup of Subjects with Suppression of HIV-1 RNA 
at Least Once to Less Than 200 Copies per Milliliter (Panel A) and Less Than 50 Copies per Milliliter (Panel B).
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renz groups (17 percent); laboratory evidence of a
grade 4 effect was found in 32 subjects (8 percent)
and 78 subjects (10 percent), respectively.
In this randomized, double-blind, placebo-con-
trolled study of initial antiretroviral regimens, we
found the triple-nucleoside-analogue regimen of
abacavir, zidovudine, and lamivudine to be virolog-
ically inferior to a regimen containing efavirenz and
two or three nucleoside analogues. This difference
was observed regardless of the pretreatment viral
load or the CD4-cell-count stratum. Since the study
population was diverse with representation from
women, nonwhites, and intravenous drug users,
these results are probably generalizable. Our find-
ings suggest that an efavirenz-containing regimen
is more potent than the triple-nucleoside regimen
and support current guidelines that recommend
efavirenz-based regimens among the preferred op-




Our study allowed substitutions of drugs within
the same classes in cases of treatment-limiting tox-
ic effects, and we followed subjects regardless of
whether they discontinued the study treatment.
This intention-to-treat approach differs from analy-
ses that consider missing data or switching drugs
as treatment failures and could account for the
higher rates of virologic suppression in our study




 We believe that
our approach better reflects the original concept of
an intention-to-treat analysis and approximates
the current clinical management of antiretroviral
therapy.
Previous studies showed that the triple-nucleo-
side regimen we used had efficacy similar to that of
regimens containing indinavir or nelfinavir, with
HIV-1 RNA levels of less than 400 copies per milli-





 Another study, in which subjects were ran-
domly assigned to receive stavudine–didanosine
with indinavir, nevirapine, or lamivudine, showed





rect comparison is the most appropriate way to as-
sess the relative efficacy of treatment regimens. Our
study suggests that although the triple-nucleoside
regimen was successful in reducing viremia in many
subjects, it was inferior to an efavirenz-containing
regimen.
In a post hoc analysis performed in order to de-
termine what to advise patients in whom viremia
was suppressed by the triple-nucleoside regimen,
we observed that subjects in the triple-nucleoside
group who had at least one HIV-1 RNA value below
200 copies per milliliter had a higher rate of viro-
logic failure than similar subjects in the efavirenz
groups. Although post hoc analyses must be inter-
preted cautiously, this analysis suggests that the
triple-nucleoside regimen may also be inferior to
an efavirenz-containing regimen in maintaining vi-
ral suppression. The optimal management for pa-
tients with suppressed viremia during treatment
with a triple-nucleoside regimen is uncertain.
Simplicity and convenience improve adherence
to antiretroviral regimens and are critical for the




The double-blind, placebo-controlled design of our
study may have reduced the convenience of the
regimens. Despite this possible effect, a median ad-
herence rate of 100 percent was reported through
week 24, without significant differences between
discussion
 
Table 2. Genotypic Resistance in the 82 Subjects in the Triple-Nucleoside 




Subjects with genotypic sequencing at baseline 81 (99)





Wild-type virus 78 (95)
Specimen not available 1 (1)
 
Samples obtained at the time of virologic failure
 
Subjects with genotypic sequencing at time of virologic 
failure
57 (70)
Substitutions associated with resistance to reverse-
transcriptase inhibitors
39 (48)
D67N, K70R, M184V, K103N, and V108I 1 
D67N, K70R, M184V, and K219E 1 
D67N, K70R, M184V, and T215Y 1 
D67N and M184V 3 
D67N and T215Y 2 
M184V 28 
M184V and T215Y 2 
M184V and V108I 1 
Wild-type virus 18 (22)
Sequencing not attempted (HIV-1 RNA level <500 copies/ml) 22 (27)
Virus could not be sequenced 3 (4)
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the treatment groups. Among the subjects who re-
ported 100 percent adherence, those who were tak-
ing the triple-nucleoside regimen had a higher rate
of virologic failure than those in the combined efa-
virenz groups. An adherence rate of more than 95
percent was associated with a better virologic re-
sponse in this study — a finding that is consistent




 Given the high
adherence rates in both groups, differential adher-
ence is unlikely to explain the differences in viro-
logic response. However, because virologic failure
occurred in patients with wild-type virus, self-
reported adherence probably represents an overes-
timate of actual adherence.
Recent studies have documented an increasing
prevalence of drug-resistant HIV-1 among previ-




and, as a consequence, an increased risk of virolog-




 In the current study,
substitutions in the viral genome were rare at base
line, suggesting that preexisting drug resistance is
unlikely to explain the higher rate of virologic fail-
ure in the triple-nucleoside group. At the time of vi-
rologic failure, viral isolates from about half the
subjects in the triple-nucleoside group showed the
M184V reverse-transcriptase substitution that is
associated with lamivudine resistance — a finding




Although the resistance data from the combined
efavirenz groups are not reported here so that we
may maintain blinding, we would expect to find the
M184V substitution, the K103N substitution asso-





The incidence of grade 3 or grade 4 adverse
events did not differ significantly between the treat-
ment groups. Substitutions of alternative drugs be-
cause of treatment-limiting toxic effects, which were
used in only 5 to 8 percent of the study subjects, re-
flect current clinical practice and permitted us to
focus on the classes of drugs rather than on specific
agents.
Treatment of HIV-1 infection continues to evolve
as new drugs and combinations are developed. Our
results demonstrate the importance of assessing
the relative efficacy of regimens through random-
ized, controlled clinical trials. In a diverse group of
previously untreated HIV-1–infected patients, the
triple-nucleoside combination of abacavir, zidovu-
dine, and lamivudine was virologically inferior to
an efavirenz-containing regimen as initial antiretro-
viral therapy. Clinicians should factor in the results
of appropriately designed, comparative studies such
as ours in selecting the optimal initial antiretroviral
regimen for an individual patient.
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